Phaseline

Targets › CD117

CD117: drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on CD117, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Actinium PharmaceuticalsIomab-B
Anti-CD117 monoclonal antibody conjugated to iodine-131
CD117Phase 3Acute Myeloid Leukemia; Non Hodgkin LymphomaDec 2026

Conditions

Acute Myeloid Leukemia (1) Non Hodgkin Lymphoma (1)

Modalities

mixed (1)

Companies

Actinium Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.